These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14650830)

  • 21. Pathological significance and prognostic roles of densities of CD57+ cells, CD68+ cells, and mast cells, and their ratios in clear cell renal cell carcinoma.
    Nakanishi H; Miyata Y; Mochizuki Y; Yasuda T; Nakamura Y; Araki K; Sagara Y; Matsuo T; Ohba K; Sakai H
    Hum Pathol; 2018 Sep; 79():102-108. PubMed ID: 29787818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The scientific and clinical results of ex vivo activated T cells for metastatic renal cell carcinoma in over 500 human patients.
    Krane RJ; Ross SD; Babbitt B; Lavin PT; Martin J; Goodwin J; Caplan B; Zhang J; Osband ME
    Cell Transplant; 1994; 3 Suppl 1():S51. PubMed ID: 8162309
    [No Abstract]   [Full Text] [Related]  

  • 23. [Renal collecting duct carcinoma associated with tumor embolus in the inferior vena cava].
    Guo LL; Wang MQ; Cai YR; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2005 Feb; 34(2):123-4. PubMed ID: 15842816
    [No Abstract]   [Full Text] [Related]  

  • 24. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
    Yu W; Wang Y; Jiang Y; Zhang W; Li Y
    BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GALNT4 predicts clinical outcome in patients with clear cell renal cell carcinoma.
    Liu Y; Liu W; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
    J Urol; 2014 Nov; 192(5):1534-41. PubMed ID: 24769034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Up-regulation of vascular endothelial growth factor-D expression in clear cell renal cell carcinoma by CD74: a critical role in cancer cell tumorigenesis.
    Liu YH; Lin CY; Lin WC; Tang SW; Lai MK; Lin JY
    J Immunol; 2008 Nov; 181(9):6584-94. PubMed ID: 18941249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma.
    Liotta F; Gacci M; Frosali F; Querci V; Vittori G; Lapini A; Santarlasci V; Serni S; Cosmi L; Maggi L; Angeli R; Mazzinghi B; Romagnani P; Maggi E; Carini M; Romagnani S; Annunziato F
    BJU Int; 2011 May; 107(9):1500-6. PubMed ID: 20735382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carcinoma in a cadaveric transplant kidney.
    Manvar AM; Rathmell WK; Ferguson J; Pruthi RS; Nielsen ME; Wallen EM; Nolan N; Raynor MC
    Urology; 2012 Apr; 79(4):758-60. PubMed ID: 22014593
    [No Abstract]   [Full Text] [Related]  

  • 29. [The clinical significance of immunohistochemically detectable Ki-67 protein in renal cell carcinoma].
    Lazarev AF; Doroshenko VS; Varlamov SA
    Vestn Ross Akad Med Nauk; 2007; (11):33-5. PubMed ID: 18080525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kidney cancer: Orchestration of immune checkpoints has prognostic value in ccRCC.
    Stone L
    Nat Rev Urol; 2015 Apr; 12(4):182. PubMed ID: 25732858
    [No Abstract]   [Full Text] [Related]  

  • 31. What advances have been made in immune-therapy for renal cell carcinoma?
    Verzoni E; Grassi P; Ratta R
    Future Oncol; 2017 Apr; 13(8):665-668. PubMed ID: 28183189
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
    Raman R; Vaena D
    Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.
    Santoni M; Buti S; Conti A; Porta C; Procopio G; Sternberg CN; Bracarda S; Basso U; De Giorgi U; Rizzo M; Derosa L; Ortega C; Massari F; Milella M; Bersanelli M; Cerbone L; Muzzonigro G; Burattini L; Montironi R; Santini D; Cascinu S
    Target Oncol; 2015 Dec; 10(4):517-22. PubMed ID: 25559290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer.
    Bromwich E; McMillan DC; Lamb GW; Vasey PA; Aitchison M
    Br J Cancer; 2004 Oct; 91(7):1236-8. PubMed ID: 15354220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Recent topics in the treatments of renal cell carcinoma].
    Eto M
    Gan To Kagaku Ryoho; 2016 Jan; 43(1):50-3. PubMed ID: 26955665
    [No Abstract]   [Full Text] [Related]  

  • 36. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
    Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
    [No Abstract]   [Full Text] [Related]  

  • 37. Pathology, biology, and clinical staging of renal cell carcinoma.
    Stenzl A; deKernion JB
    Semin Oncol; 1989 Feb; 16(1 Suppl 1):3-11. PubMed ID: 2645654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies to overcome therapeutic resistance in renal cell carcinoma.
    Siska PJ; Beckermann KE; Rathmell WK; Haake SM
    Urol Oncol; 2017 Mar; 35(3):102-110. PubMed ID: 28089416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
    Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
    BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma.
    Kondo T; Ito F; Nakazawa H; Horita S; Osaka Y; Toma H
    J Urol; 2004 Jun; 171(6 Pt 1):2171-5. PubMed ID: 15126779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.